CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

CAMP4 (Nasdaq: CAMP) announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 3:45 p.m. PST.

The presentation will be webcast and accessible via CAMP4's investor relations website at www.investors.camp4tx.com. A replay will be archived on the CAMP4 website for 30 days following the conference.

Market Context

This announcement details a corporate update at the 44th J.P. Morgan Healthcare Conference on Januar...

Analysis

This announcement details a corporate update at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, continuing CAMP’s recent cadence of financings, partnerships, and pipeline disclosures. Investors may contextualize this visibility alongside the November S-3 shelf for up to $300,000,000, recent equity offerings, and the GSK collaboration with $17.5M upfront and up to $440M in milestones. Future attention will likely focus on clinical progress timelines and additional capital-raising actions.

Key Figures

Conference edition: 44th annual Presentation date: January 14, 2026 Presentation time: 3:45 p.m. PST +1 more

4 metrics

Conference edition 44th annual J.P. Morgan Healthcare Conference

Presentation date January 14, 2026 Corporate update presentation timing

Presentation time 3:45 p.m. PST Scheduled slot at J.P. Morgan conference

Webcast replay period 30 days Replay availability on company website

Historical Context

5 past events · Latest: Dec 18 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 18	Equity offering	Negative	-12.9%	Underwritten common stock offering for $30.0M gross proceeds at $6.00.
Dec 18	Strategic partnership	Positive	-12.9%	GSK collaboration with $17.5M upfront and milestones for ASO discovery.
Dec 12	Inducement grants	Neutral	+4.0%	Inducement options for 92,000 shares at $6.01 to new employees.
Nov 14	Inducement grant	Neutral	-2.7%	Single inducement option for 80,000 shares at $4.39 to a new hire.
Nov 06	Earnings & update	Positive	+7.0%	Q3 2025 results, private placement up to $100M, cash of $75.3M, and pipeline progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often led to aligned reactions, with financings drawing negative moves and positive corporate/clinical updates generally seeing supportive price action, except for the GSK collaboration selloff.

Recent Company History

Over the last few months, CAMP has balanced financing, partnerships, and pipeline progress. A Q3 2025 update on Nov 6 highlighted a private placement of up to $100M, cash of $75.3M, and clinical advances, with shares rising 6.97%. Subsequent inducement option grants in November and December 2025 had modest, mixed reactions. On Dec 18, a $30.0M underwritten offering and a sizable GSK collaboration with $17.5M upfront saw the stock fall 12.9%, showing sensitivity to dilution despite strategic progress. Today’s conference appearance fits into this ongoing communication cadence.

Key Terms

regulatory rna-targeting therapeutics, gene expression, webcast

3 terms

regulatory rna-targeting therapeutics medical

"a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression"

Regulatory RNA-targeting therapeutics are medicines designed to change how cells read their internal instruction manuals by binding to small RNA molecules that control gene activity. Like using a sticky note to hide or highlight a paragraph in a manual, these drugs can dial up or down production of specific proteins, offering precise ways to treat disease; investors care because they promise targeted benefits but come with high scientific, regulatory and commercial risk and potential payoff.

gene expression medical

"therapeutics designed to upregulate gene expression with the goal of restoring healthy protein"

Gene expression is the process by which a cell reads a gene’s instructions and produces the molecules—usually proteins—that do work in the body, like building structures or sending signals. Think of a gene as a recipe and expression as the act of cooking: whether and how much a dish gets made affects the final product. Investors care because changes in gene expression underlie diseases, treatment responses, biomarkers and drug targets, so they can influence clinical outcomes, regulatory decisions and commercial value.

webcast technical

"The event will be webcast and can be accessed on the investor relations page"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44^th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST.

The event will be webcast and can be accessed on the investor relations page of CAMP4’s website at www.investors.camp4tx.com. A replay of the webcast will be archived on the CAMP4 website for 30 days following the conference.

About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform^® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

FAQ

When will CAMP4 (CAMP) present at the J.P. Morgan Healthcare Conference?

CAMP4 will present on January 14, 2026 at 3:45 p.m. PST.

Who will deliver CAMP4's corporate update at the J.P. Morgan Healthcare Conference?

Josh Mandel-Brehm, President & CEO of CAMP4, will deliver the corporate update.

How can investors watch CAMP4's webcast for the January 14, 2026 presentation?

The presentation will be webcast on CAMP4's investor relations site at www.investors.camp4tx.com.

Will CAMP4's J.P. Morgan presentation be available after the live event?

Yes. A replay will be archived on CAMP4's website for 30 days after the conference.

What topics will CAMP4 (CAMP) cover in the January 14, 2026 corporate update?

The corporate update will cover CAMP4's recent clinical-stage developments and company outlook, as presented by management.